...
首页> 外文期刊>Life sciences >IRREVERSIBLE BINDING OF N-METHYL-N-[(1S)-1-(4-ISOTHIOCYANATOPHENYL)-2-(1-PYRROLIDINYL)ETHYL-3,4-DI CHLOROPHENYLACETAMIDE TO THE CLONED RAT KAPPA OPIOID RECEPTOR
【24h】

IRREVERSIBLE BINDING OF N-METHYL-N-[(1S)-1-(4-ISOTHIOCYANATOPHENYL)-2-(1-PYRROLIDINYL)ETHYL-3,4-DI CHLOROPHENYLACETAMIDE TO THE CLONED RAT KAPPA OPIOID RECEPTOR

机译:N-甲基-N-[(1S)-1-(4-异硫代环庚基苯基)-2-(1-吡咯烷基)乙基-3,4-二氯苯乙酰胺不可克隆地与克隆的大鼠κ阿片受体结合

获取原文
获取原文并翻译 | 示例
           

摘要

N-Methyl-N-[(1S)-1-(4-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl-3,4-di chlorophenylacetamide (MITPD)(1), is an isothiocyanate derivative of the kappa agonist ICI-199,441. In this study, interaction of MITPD with cloned mu, delta, and kappa opioid receptors was characterized. MITPD inhibited [H-3]diprenorphine binding to kappa receptors with high affinity and with similar to 700- and similar to 870-fold selectivity over mu and delta receptors. Pretreatment with MITPD followed by extensive washing reduced kappa receptor binding with an IC50 value of 3.7 nM, but did not affect mu or delta binding at I 0.1 mu M. Preincubation with I mu M MITPD abolished [H-3]diprenorphine binding, while pretreatment with 1 mu M ICI-199,441 increased K-d of [H-3]diprenorphine binding with no change in B-max. Thus, MITPD is a selective kappa irreversible ligand. The region of the kappa receptor that conferred selectivity for MITPD was determined by examining its binding to four mu/kappa chimeras. IC50 values of MITPD for inhibition of [H-3]diprenorphine binding were determined to be 430 nM for Chimera III (kappa 1-141/mu 151-398), 1.8 nM for Chimera IV (mu 1-150/kappa 142-380), 40 nM for Chimera XI (mu 1-268/kappa 263-380) and 14 nM for Chimera XII (kappa 1-262/mu 269-398). Pretreatment with MITPD followed by extensive washing reduced binding to chimera IV with an IC50 value of 75 nM, but did not affect III, XI or XII binding (IC50 >1 mu M). Thus, the region from the third transmembrane helix to the C-terminus of the kappa receptor is important for the binding of MITPD. [References: 38]
机译:N-甲基-N-[((1S)-1-(4-异硫氰酸根合苯基)-2-(1-吡咯烷基)乙基-3,4-二氯苯基乙酰胺(MITPD)(1))是κ激动剂ICI的异硫氰酸酯衍生物-199,441。在这项研究中,表征了MITPD与克隆的mu,delta和kappa阿片受体的相互作用。 MITPD抑制[H-3] diprenorphine与kappa受体的结合具有很高的亲和力,并且选择性比mu和delta受体高700倍和类似870倍。用MITPD预处理,然后进行大量洗涤,可降低kappa受体结合,IC50值为3.7 nM,但不影响μ0.1时的mu或delta结合。用IμM MITPD进行预孵育可消除[H-3] diprenorphine结合,同时进行预处理具有1μMMICI-199,441的[H-3] diprenorphine结合的Kd增加,而B-max没有变化。因此,MITPD是选择性κ不可逆配体。通过检查其与四种mu /κ嵌合体的结合来确定赋予MITPD选择性的κ受体区域。抑制[H-3] diprenorphine结合的MITPD的IC50值对于Chimera III(kappa 1-141 / mu 151-398)确定为430 nM,对于Chimera IV(mu 1-150 / kappa 142-380)为1.8 nM。 ),对于Chimera XI为40 nM(μ1-268 / kappa 263-380),对于Chimera XII为14 nM(kappa 1-262 / mu 269-398)。用MITPD预处理,然后进行大量洗涤,降低了与嵌合体IV的结合,IC50值为75 nM,但不影响III,XI或XII结合(IC50> 1μM)。因此,从第三跨膜螺旋到κ受体的C末端的区域对于MITPD的结合是重要的。 [参考:38]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号